Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata, Liq-E S.A. De C.V. received an FDA Warning Letter on November 19, 2020, regarding drug products. Without access to the full letter text or detailed subject information, the specific nature of the violations cannot be definitively determined from the available metadata. The warning was issued under FDA's drug regulatory authority, indicating the company's operations or manufacturing practices did not meet federal requirements. Additional details about the particular violations and remediation expectations would require review of the complete Warning Letter document.